Sage Therapeutics, Inc.
SAGE
$7.93
$0.070.89%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -52.30% | 837.52% | 837.56% | 868.87% | 1,024.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.30% | 837.52% | 837.56% | 868.87% | 1,024.70% |
| Cost of Revenue | -33.70% | -26.39% | -12.00% | 2.89% | 13.67% |
| Gross Profit | 28.06% | 53.29% | 37.09% | 21.60% | 10.67% |
| SG&A Expenses | -21.16% | -24.36% | -10.47% | 5.86% | 20.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.62% | -28.47% | -13.44% | 1.88% | 14.11% |
| Operating Income | 24.88% | 43.40% | 27.65% | 12.19% | 0.10% |
| Income Before Tax | 26.01% | 48.53% | 24.67% | 9.76% | -1.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.01% | 48.53% | 24.67% | 9.76% | -1.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.01% | 48.53% | 24.67% | 9.76% | -1.63% |
| EBIT | 24.88% | 43.40% | 27.65% | 12.19% | 0.10% |
| EBITDA | 24.87% | 43.49% | 27.73% | 12.25% | 0.15% |
| EPS Basic | 27.13% | 49.20% | 25.32% | 10.43% | -0.79% |
| Normalized Basic EPS | 26.55% | 46.43% | 30.93% | 16.37% | 5.41% |
| EPS Diluted | 27.13% | 49.20% | 25.32% | 10.43% | -0.77% |
| Normalized Diluted EPS | 26.55% | 46.43% | 30.93% | 16.37% | 5.41% |
| Average Basic Shares Outstanding | 1.55% | 1.23% | 0.93% | 0.82% | 0.90% |
| Average Diluted Shares Outstanding | 1.55% | 1.23% | 0.93% | 0.82% | 0.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
